When was Ionetix founded?

Ionetix was founded in 2009 and raised its 1st funding round 9 years after it was founded.

Where is Ionetix located?

Ionetix is headquartered in San Francisco, United States.

How many employees does Ionetix have?

As of Mar 31, 2026, the latest employee count at Ionetix is 57.

Is Ionetix a funded company?

Ionetix is a funded company, having raised a total of $61.1M across 4 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 09, 2018.

When was the latest funding round of Ionetix?

Ionetix's latest funding was a $***** Post IPO round on Feb 24, 2026, with participation from 0 investor.

Where does Ionetix rank among its competitors?

Ionetix ranks 14th amongst 97 active competitors, of which 23 are funded. It stands 4th in terms of total funding among its competitors.

Who are the top competitors of Ionetix?

Ionetix's top competitors include ImaginAb, Conavi and Curium. Among them, Ionetix secured the most recent funding round in February, 2026.

Ionetix - 2026 Company Profile, Team, Funding & Competitors

Ionetix is a series C company based in San Francisco (United States), founded in 2009. It operates as a Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy. Ionetix has raised $61.1M in funding from Lilly. The company has 97 active competitors, including 23 funded and 16 that have exited. Its top competitors include companies like ImaginAb, Conavi and Curium.

Company Details

Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy. The company provides full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions. It developed a compact superconducting cyclotron used to produce N-13 Ammonia, a PET imaging agent. The company establishes a network of cyclotrons installed near PET programs, making this tracer accessible and affordable. It supports the development and commercialization of targeted alpha therapy (TAT), an emerging cancer therapy utilizing alpha radionuclides. The company is committed to the design, manufacturing, and support of safe and effective radiopharmaceutical products. It offers a turnkey solution eliminating the expense of launching a Cardiac PET program. The company fosters scientific partnerships and sponsorships to deliver advanced radiopharmaceuticals, providing access to scarce diagnostics and therapeutic radiopharmaceuticals.

Website: www.ionetix.com/
Email ID: *****@ionetix.com

Key Metrics

Founded Year

2009

Location

San Francisco, United States

Stage

Series C

Total Funding

$61.1M in 4 rounds

Latest Funding Round

Post IPO, Feb 24, 2026, $*****

Investors

Lilly & 2 more

Ranked

14^th among 97 active competitors

Employee Count

57 as on Mar 31, 2026

Similar Companies

ImaginAb & 126 more

View Ionetix's full profile

Ionetix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ionetix Corporation CIN: - , Belgium, Active	Dec 28, 2009	-	-	-

Ionetix has raised a total funding of $61.1M over 4 rounds. Its first funding round was on Mar 09, 2018. Ionetix has 3 institutional investors.

Here is the list of recent funding rounds of Ionetix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 24, 2026	3223595	Post IPO	7208257	1704501	5035672	4093437
Aug 07, 2024	1101853	Series C	7026331	5301321	7499731	Tees River
May 05, 2020	8673986	Series C	8650759	3891816	2275232	1867427

Access funding benchmarks and valuations. Sign up today!

View details of Ionetix's funding rounds and investors

Ionetix's employee count trend

Ionetix has 57 employees as of Mar 26. Here is Ionetix's employee count trend over the years:

Uncover Ionetix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ionetix include ImaginAb, Conavi and Curium. Here is the list of Top 10 competitors of Ionetix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ImaginAb 2007, Los Angeles (United States), Series C	Immune imaging technology for cancer and autoimmune disease management	$59.6M	Adage Capital Management, Novartis Venture Fund ... & 12 others	61/100
2nd	Conavi 2007, Toronto (Canada), Public	A catheter-based ultrasound system for cardiac imaging	$43.2M	MaRS Discovery District, FedDev Ontario & 5 others	60/100
3rd	Curium 2017, Paris (France), Seed	Specialty developer, manufacturer & distributor of radiopharmaceuticals	-	CapVest	56/100
4th	AC Immune 2003, Lausanne (Switzerland), Public	Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases	$120M	BVF Partners, Redmile Group & 4 others	54/100
5th	APRINOIA 2015, Taipei (Taiwan), Series C	Developer of diagnostics and therapeutics for neurodegenerative disorders	$51.1M	DAOL Investment, The Michael J. Fox Foundation ... & 10 others	49/100
6th	Telix Pharma 2015, Melbourne (Australia), Public	Developer of theranostic radiopharmaceuticals for imaging and treating cancer	-	China Grand Pharmaceutical and Healthcare	49/100
7th	Acarix 2009, Kongens Lyngby (Denmark), Public	Provider of a screening device for acoustic coronary artery diseases	$9.97M	Seventure Partners, Sunstone & 2 others	48/100
8th	Blue Earth Diagnostics 2014, Oxford (United Kingdom), Acquired	Developer of radioactive molecular imaging agents for cancer	$49.4M	Syncona	47/100
9th	RadioMedix 2006, Houston (United States), Series A	Developer of targeted radiopharmaceuticals for cancer diagnosis and treatment	$40M	HHS, Portland	46/100
10th	BioArctic 2003, Bromma (Sweden), Public	Developer of disease-modifying treatments for neurodegenerative diseases	-	European Union, EIC Fund	45/100
14th	Ionetix 2009, San Francisco (United States), Series C	Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy	$61.1M	Lilly, Riverland Capital & 1 others	56/100